skinny.

Latest / Lung Cancer Considered

FDA Approval Zenocutuzumab For NRG1 Fusion Cancers

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of zenocutuzumab for NSCLC with an NRG1 fusion. NRG1 fusions are rare but important events seen in many cancer types, including NSCLC. Zenocutuzumab is a HER2/HER3 bispecific antibody that showed clear efficacy in NSCLC and in pancreatic cancer that harbored an NRG1 fusion. Guest: Dr. Alison Schram, Assistant Attending Physician and Section Head of Oral Therapeutics in Early Drug Development at Memorial Sloan Kettering Cancer Center in New York

Log in to save or queue this episode.

The skinny

The skinny isn't ready yet — notes appear once the transcript is processed.